Journal article
Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review
Seminars in arthritis and rheumatism, Vol.50(5), pp.1191-1201
10/01/2020
DOI: 10.1016/j.semarthrit.2020.07.007
PMCID: PMC7832282
PMID: 32931985
Abstract
Introduction: COVID-19 is an acute respiratory viral infection that threatens people worldwide, including people with rheumatic disease, although it remains unclear to what extent various antirheumatic disease therapies increase susceptibility to complications of viral respiratory infections.
Objective: The present study undertakes a scoping review of available evidence regarding the frequency and severity of acute respiratory viral adverse events related to antirheumatic disease therapies.
Methods: Online databases were used to identify, since database inception, studies reporting primary data on acute respiratory viral infections in patients utilizing antirheumatic disease therapies. Independent reviewer pairs charted data from eligible studies using a standardized data abstraction tool.
Results: A total of 180 studies were eligible for qualitative analysis. While acknowledging that the extant literature has a lack of specificity in reporting of acute viral infections or complications thereof, the data suggest that use of glucocorticoids, JAK inhibitors (especially high-dose), TNF inhibitors, and anti-IL-17 agents may be associated with an increased frequency of respiratory viral events. Available data suggest no increased frequency or risk of respiratory viral events with NSAIDs, hydroxychloroquine, sulfasalazine, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, or apremilast. One large cohort study demonstrated an association with leflunomide use and increased risk of acute viral respiratory events compared to non-use.
Conclusion: This scoping review identified that some medication classes may confer increased risk of acute respiratory viral infections. However, definitive data are lacking and future studies should address this knowledge gap. (C) 2020 Elsevier Inc. All rights reserved.
Details
- Title: Subtitle
- Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review
- Creators
- Adam Kilian - George Washington UniversityYu Pei Chock - Yale UniversityIrvin J. Huang - University of WashingtonElizabeth R. Graef - Beth Israel Deaconess Medical CenterLaura A. Upton - Georgetown UniversityAneka Khilnani - George Washington UniversitySonia D. Silinsky Krupnikova - George Washington UniversityIbrahim Almaghlouth - King Saud UniversityLaura C. Cappelli - Johns Hopkins MedicineRuth Fernandez-Ruiz - NYU Langone HealthBrittany A. Frankel - University of WashingtonJourdan Frankovich - Temple UniversityCarly Harrison - LupusChatBharat Kumar - University of IowaKanika Monga - The University of Texas Health Science Center at HoustonJorge A. Rosario Vega - Temple UniversityNamrata Singh - University of WashingtonJeffrey A. Sparks - Brigham and Women's HospitalElaine Sullo - George Washington UniversityKristen J. Young - The University of Texas Southwestern Medical CenterAli Duarte-Garcia - Mayo Clinic in ArizonaMichael Putman - Northwestern MedicineSindhu Johnson - Mount Sinai HospitalRebecca Grainger - University of OtagoZachary S. Wallace - Massachusetts General HospitalJean W. Liew - University of WashingtonAruni Jayatilleke - Temple University
- Resource Type
- Journal article
- Publication Details
- Seminars in arthritis and rheumatism, Vol.50(5), pp.1191-1201
- DOI
- 10.1016/j.semarthrit.2020.07.007
- PMID
- 32931985
- PMCID
- PMC7832282
- NLM abbreviation
- Semin Arthritis Rheum
- ISSN
- 0049-0172
- eISSN
- 1532-866X
- Publisher
- Elsevier
- Number of pages
- 11
- Grant note
- Janssen (Johnson Johnson); Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc Amgen
- Language
- English
- Date published
- 10/01/2020
- Academic Unit
- Epidemiology; Immunology; Internal Medicine
- Record Identifier
- 9984359857702771
Metrics
28 Record Views